Needham Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $6
Needham Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $6
Needham維持對taysha gene therapies的買入評級,但將目標價下調至6美元。
Needham analyst Gil Blum maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and lowers the price target from $7 to $6.
Needham分析師Gil Blum認爲Taysha Gene Therapies (NASDAQ:納斯達克TSHA)值得買入,並將目標股價從7美元降至6美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。